

Global Angiogenesis Therapeutic Agent Market Growth 2023-2029

https://marketpublishers.com/r/G44B82335DEFEN.html

Date: May 2023

Pages: 129

Price: US\$ 3,660.00 (Single User License)

ID: G44B82335DEFEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Angiogenesis Therapeutic Agent market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Angiogenesis Therapeutic Agent is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Angiogenesis Therapeutic Agent is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Angiogenesis Therapeutic Agent is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Angiogenesis Therapeutic Agent players cover Gilead Sciences, Inc., Eyetech Inc., Becton, Dickinson and Company, Regeneron Pharmaceuticals, Inc., Genentech, Inc., Novartis AG, Allergan plc, Bayer AG and Santen Pharmaceutical Co., Ltd., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Anti-angiogenic ophthalmic agents act as antagonists against the vascular endothelial growth factor (VEGF). When retinal pigment cells become ischemic and dry up VEGF stimulates generation of new blood vessels by a process called neovascularization. If new blood vessels are not generated properly, leakage occurs in retina, which leads to vision loss. Angiogenesis plays an important role in chronic inflammation and fibrosis,



tumor growth and vascularization of ischemic tissue.

LPI (LP Information)' newest research report, the "Angiogenesis Therapeutic Agent Industry Forecast" looks at past sales and reviews total world Angiogenesis Therapeutic Agent sales in 2022, providing a comprehensive analysis by region and market sector of projected Angiogenesis Therapeutic Agent sales for 2023 through 2029. With Angiogenesis Therapeutic Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Angiogenesis Therapeutic Agent industry.

This Insight Report provides a comprehensive analysis of the global Angiogenesis Therapeutic Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiogenesis Therapeutic Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiogenesis Therapeutic Agent market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiogenesis Therapeutic Agent and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiogenesis Therapeutic Agent.

This report presents a comprehensive overview, market shares, and growth opportunities of Angiogenesis Therapeutic Agent market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Myopic Choroidal Neovascularization


Macular Edema

Diabetic Retinopathy



Macular Degeneration Segmentation by application **Retail Pharmacies** Online Pharmacies **Hospital Pharmacies** This report also splits the market by region: Americas **United States** Canada Mexico Brazil **APAC** China Japan Korea Southeast Asia India Australia







Novartis AG
Allergan plc
Bayer AG
Santen Pharmaceutical Co., Ltd.
Shanghai Pharmaceuticals
Johnson & Johnson
Pfizer
Sun Pharma
Otsuka Pharmaceutical Co. Ltd
Daiichi Sankyo
ERC Labs
Medicom Health care
Implandata ophthalmic products GmbH
The Geuder Group, MORCHER GmbH
Novamedika
Key Questions Addressed in this Report
What is the 10-year outlook for the global Angiogenesis Therapeutic Agent market?
What factors are driving Angiogenesis Therapeutic Agent market growth, globally and

Which technologies are poised for the fastest growth by market and region?

by region?



How do Angiogenesis Therapeutic Agent market opportunities vary by end market size?

How does Angiogenesis Therapeutic Agent break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Angiogenesis Therapeutic Agent Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Angiogenesis Therapeutic Agent by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Angiogenesis Therapeutic Agent by Country/Region, 2018, 2022 & 2029
- 2.2 Angiogenesis Therapeutic Agent Segment by Type
 - 2.2.1 Myopic Choroidal Neovascularization
 - 2.2.2 Macular Edema
 - 2.2.3 Diabetic Retinopathy
 - 2.2.4 Macular Degeneration
- 2.3 Angiogenesis Therapeutic Agent Sales by Type
- 2.3.1 Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
- 2.3.2 Global Angiogenesis Therapeutic Agent Revenue and Market Share by Type (2018-2023)
- 2.3.3 Global Angiogenesis Therapeutic Agent Sale Price by Type (2018-2023)
- 2.4 Angiogenesis Therapeutic Agent Segment by Application
 - 2.4.1 Retail Pharmacies
 - 2.4.2 Online Pharmacies
 - 2.4.3 Hospital Pharmacies
- 2.5 Angiogenesis Therapeutic Agent Sales by Application
- 2.5.1 Global Angiogenesis Therapeutic Agent Sale Market Share by Application (2018-2023)



- 2.5.2 Global Angiogenesis Therapeutic Agent Revenue and Market Share by Application (2018-2023)
- 2.5.3 Global Angiogenesis Therapeutic Agent Sale Price by Application (2018-2023)

3 GLOBAL ANGIOGENESIS THERAPEUTIC AGENT BY COMPANY

- 3.1 Global Angiogenesis Therapeutic Agent Breakdown Data by Company
- 3.1.1 Global Angiogenesis Therapeutic Agent Annual Sales by Company (2018-2023)
- 3.1.2 Global Angiogenesis Therapeutic Agent Sales Market Share by Company (2018-2023)
- 3.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Company (2018-2023)
- 3.2.1 Global Angiogenesis Therapeutic Agent Revenue by Company (2018-2023)
- 3.2.2 Global Angiogenesis Therapeutic Agent Revenue Market Share by Company (2018-2023)
- 3.3 Global Angiogenesis Therapeutic Agent Sale Price by Company
- 3.4 Key Manufacturers Angiogenesis Therapeutic Agent Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Angiogenesis Therapeutic Agent Product Location Distribution
- 3.4.2 Players Angiogenesis Therapeutic Agent Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR ANGIOGENESIS THERAPEUTIC AGENT BY GEOGRAPHIC REGION

- 4.1 World Historic Angiogenesis Therapeutic Agent Market Size by Geographic Region (2018-2023)
- 4.1.1 Global Angiogenesis Therapeutic Agent Annual Sales by Geographic Region (2018-2023)
- 4.1.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Angiogenesis Therapeutic Agent Market Size by Country/Region (2018-2023)
- 4.2.1 Global Angiogenesis Therapeutic Agent Annual Sales by Country/Region (2018-2023)



- 4.2.2 Global Angiogenesis Therapeutic Agent Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Angiogenesis Therapeutic Agent Sales Growth
- 4.4 APAC Angiogenesis Therapeutic Agent Sales Growth
- 4.5 Europe Angiogenesis Therapeutic Agent Sales Growth
- 4.6 Middle East & Africa Angiogenesis Therapeutic Agent Sales Growth

5 AMERICAS

- 5.1 Americas Angiogenesis Therapeutic Agent Sales by Country
- 5.1.1 Americas Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
- 5.1.2 Americas Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)
- 5.2 Americas Angiogenesis Therapeutic Agent Sales by Type
- 5.3 Americas Angiogenesis Therapeutic Agent Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Angiogenesis Therapeutic Agent Sales by Region
 - 6.1.1 APAC Angiogenesis Therapeutic Agent Sales by Region (2018-2023)
- 6.1.2 APAC Angiogenesis Therapeutic Agent Revenue by Region (2018-2023)
- 6.2 APAC Angiogenesis Therapeutic Agent Sales by Type
- 6.3 APAC Angiogenesis Therapeutic Agent Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Angiogenesis Therapeutic Agent by Country
- 7.1.1 Europe Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
- 7.1.2 Europe Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)



- 7.2 Europe Angiogenesis Therapeutic Agent Sales by Type
- 7.3 Europe Angiogenesis Therapeutic Agent Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Angiogenesis Therapeutic Agent by Country
- 8.1.1 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Country (2018-2023)
- 8.1.2 Middle East & Africa Angiogenesis Therapeutic Agent Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Type
- 8.3 Middle East & Africa Angiogenesis Therapeutic Agent Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Angiogenesis Therapeutic Agent
- 10.3 Manufacturing Process Analysis of Angiogenesis Therapeutic Agent
- 10.4 Industry Chain Structure of Angiogenesis Therapeutic Agent

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel



- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Angiogenesis Therapeutic Agent Distributors
- 11.3 Angiogenesis Therapeutic Agent Customer

12 WORLD FORECAST REVIEW FOR ANGIOGENESIS THERAPEUTIC AGENT BY GEOGRAPHIC REGION

- 12.1 Global Angiogenesis Therapeutic Agent Market Size Forecast by Region
 - 12.1.1 Global Angiogenesis Therapeutic Agent Forecast by Region (2024-2029)
- 12.1.2 Global Angiogenesis Therapeutic Agent Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Angiogenesis Therapeutic Agent Forecast by Type
- 12.7 Global Angiogenesis Therapeutic Agent Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Gilead Sciences, Inc.
 - 13.1.1 Gilead Sciences, Inc. Company Information
- 13.1.2 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.1.3 Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Gilead Sciences, Inc. Main Business Overview
 - 13.1.5 Gilead Sciences, Inc. Latest Developments
- 13.2 Eyetech Inc.
 - 13.2.1 Eyetech Inc. Company Information
- 13.2.2 Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.2.3 Eyetech Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Eyetech Inc. Main Business Overview
 - 13.2.5 Eyetech Inc. Latest Developments
- 13.3 Becton, Dickinson and Company
- 13.3.1 Becton, Dickinson and Company Company Information



- 13.3.2 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.3.3 Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.3.4 Becton, Dickinson and Company Main Business Overview
- 13.3.5 Becton, Dickinson and Company Latest Developments
- 13.4 Regeneron Pharmaceuticals, Inc.
 - 13.4.1 Regeneron Pharmaceuticals, Inc. Company Information
- 13.4.2 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.4.3 Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.4.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
- 13.4.5 Regeneron Pharmaceuticals, Inc. Latest Developments
- 13.5 Genentech, Inc.
 - 13.5.1 Genentech, Inc. Company Information
- 13.5.2 Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.5.3 Genentech, Inc. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 Genentech, Inc. Main Business Overview
 - 13.5.5 Genentech, Inc. Latest Developments
- 13.6 Novartis AG
 - 13.6.1 Novartis AG Company Information
- 13.6.2 Novartis AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.6.3 Novartis AG Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Novartis AG Main Business Overview
 - 13.6.5 Novartis AG Latest Developments
- 13.7 Allergan plc
 - 13.7.1 Allergan plc Company Information
- 13.7.2 Allergan plc Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.7.3 Allergan plc Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.7.4 Allergan plc Main Business Overview
 - 13.7.5 Allergan plc Latest Developments
- 13.8 Bayer AG



- 13.8.1 Bayer AG Company Information
- 13.8.2 Bayer AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.8.3 Bayer AG Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.8.4 Bayer AG Main Business Overview
 - 13.8.5 Bayer AG Latest Developments
- 13.9 Santen Pharmaceutical Co., Ltd.
 - 13.9.1 Santen Pharmaceutical Co., Ltd. Company Information
- 13.9.2 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.9.3 Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.9.4 Santen Pharmaceutical Co., Ltd. Main Business Overview
- 13.9.5 Santen Pharmaceutical Co., Ltd. Latest Developments
- 13.10 Shanghai Pharmaceuticals
 - 13.10.1 Shanghai Pharmaceuticals Company Information
- 13.10.2 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.10.3 Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.10.4 Shanghai Pharmaceuticals Main Business Overview
 - 13.10.5 Shanghai Pharmaceuticals Latest Developments
- 13.11 Johnson & Johnson
 - 13.11.1 Johnson & Johnson Company Information
- 13.11.2 Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.11.3 Johnson & Johnson Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.11.4 Johnson & Johnson Main Business Overview
 - 13.11.5 Johnson & Johnson Latest Developments
- 13.12 Pfizer
 - 13.12.1 Pfizer Company Information
 - 13.12.2 Pfizer Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.12.3 Pfizer Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.12.4 Pfizer Main Business Overview
 - 13.12.5 Pfizer Latest Developments
- 13.13 Sun Pharma



- 13.13.1 Sun Pharma Company Information
- 13.13.2 Sun Pharma Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.13.3 Sun Pharma Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.13.4 Sun Pharma Main Business Overview
 - 13.13.5 Sun Pharma Latest Developments
- 13.14 Otsuka Pharmaceutical Co. Ltd
- 13.14.1 Otsuka Pharmaceutical Co. Ltd Company Information
- 13.14.2 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.14.3 Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.14.4 Otsuka Pharmaceutical Co. Ltd Main Business Overview
- 13.14.5 Otsuka Pharmaceutical Co. Ltd Latest Developments
- 13.15 Daiichi Sankyo
 - 13.15.1 Daiichi Sankyo Company Information
- 13.15.2 Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.15.3 Daiichi Sankyo Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.15.4 Daiichi Sankyo Main Business Overview
 - 13.15.5 Daiichi Sankyo Latest Developments
- 13.16 ERC Labs
 - 13.16.1 ERC Labs Company Information
- 13.16.2 ERC Labs Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.16.3 ERC Labs Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.16.4 ERC Labs Main Business Overview
 - 13.16.5 ERC Labs Latest Developments
- 13.17 Medicom Health care
 - 13.17.1 Medicom Health care Company Information
- 13.17.2 Medicom Health care Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.17.3 Medicom Health care Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.17.4 Medicom Health care Main Business Overview
 - 13.17.5 Medicom Health care Latest Developments



- 13.18 Implandata ophthalmic products GmbH
 - 13.18.1 Implandata ophthalmic products GmbH Company Information
- 13.18.2 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.18.3 Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.18.4 Implandata ophthalmic products GmbH Main Business Overview
 - 13.18.5 Implandata ophthalmic products GmbH Latest Developments
- 13.19 The Geuder Group, MORCHER GmbH
 - 13.19.1 The Geuder Group, MORCHER GmbH Company Information
- 13.19.2 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.19.3 The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.19.4 The Geuder Group, MORCHER GmbH Main Business Overview
- 13.19.5 The Geuder Group, MORCHER GmbH Latest Developments
- 13.20 Novamedika
 - 13.20.1 Novamedika Company Information
- 13.20.2 Novamedika Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- 13.20.3 Novamedika Angiogenesis Therapeutic Agent Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.20.4 Novamedika Main Business Overview
 - 13.20.5 Novamedika Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES

- Table 1. Angiogenesis Therapeutic Agent Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Angiogenesis Therapeutic Agent Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of Myopic Choroidal Neovascularization
- Table 4. Major Players of Macular Edema
- Table 5. Major Players of Diabetic Retinopathy
- Table 6. Major Players of Macular Degeneration
- Table 7. Global Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)
- Table 8. Global Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
- Table 9. Global Angiogenesis Therapeutic Agent Revenue by Type (2018-2023) & (\$ million)
- Table 10. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2023)
- Table 11. Global Angiogenesis Therapeutic Agent Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 12. Global Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)
- Table 13. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
- Table 14. Global Angiogenesis Therapeutic Agent Revenue by Application (2018-2023)
- Table 15. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application (2018-2023)
- Table 16. Global Angiogenesis Therapeutic Agent Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 17. Global Angiogenesis Therapeutic Agent Sales by Company (2018-2023) & (K Units)
- Table 18. Global Angiogenesis Therapeutic Agent Sales Market Share by Company (2018-2023)
- Table 19. Global Angiogenesis Therapeutic Agent Revenue by Company (2018-2023) (\$ Millions)
- Table 20. Global Angiogenesis Therapeutic Agent Revenue Market Share by Company (2018-2023)
- Table 21. Global Angiogenesis Therapeutic Agent Sale Price by Company (2018-2023)



& (US\$/Unit)

Table 22. Key Manufacturers Angiogenesis Therapeutic Agent Producing Area Distribution and Sales Area

Table 23. Players Angiogenesis Therapeutic Agent Products Offered

Table 24. Angiogenesis Therapeutic Agent Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 25. New Products and Potential Entrants

Table 26. Mergers & Acquisitions, Expansion

Table 27. Global Angiogenesis Therapeutic Agent Sales by Geographic Region (2018-2023) & (K Units)

Table 28. Global Angiogenesis Therapeutic Agent Sales Market Share Geographic Region (2018-2023)

Table 29. Global Angiogenesis Therapeutic Agent Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 30. Global Angiogenesis Therapeutic Agent Revenue Market Share by Geographic Region (2018-2023)

Table 31. Global Angiogenesis Therapeutic Agent Sales by Country/Region (2018-2023) & (K Units)

Table 32. Global Angiogenesis Therapeutic Agent Sales Market Share by Country/Region (2018-2023)

Table 33. Global Angiogenesis Therapeutic Agent Revenue by Country/Region (2018-2023) & (\$ millions)

Table 34. Global Angiogenesis Therapeutic Agent Revenue Market Share by Country/Region (2018-2023)

Table 35. Americas Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)

Table 36. Americas Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)

Table 37. Americas Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & (\$ Millions)

Table 38. Americas Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)

Table 39. Americas Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)

Table 40. Americas Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)

Table 41. APAC Angiogenesis Therapeutic Agent Sales by Region (2018-2023) & (K Units)

Table 42. APAC Angiogenesis Therapeutic Agent Sales Market Share by Region



(2018-2023)

Table 43. APAC Angiogenesis Therapeutic Agent Revenue by Region (2018-2023) & (\$ Millions)

Table 44. APAC Angiogenesis Therapeutic Agent Revenue Market Share by Region (2018-2023)

Table 45. APAC Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)

Table 46. APAC Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)

Table 47. Europe Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)

Table 48. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)

Table 49. Europe Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & (\$ Millions)

Table 50. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)

Table 51. Europe Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)

Table 52. Europe Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)

Table 53. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Country (2018-2023) & (K Units)

Table 54. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Country (2018-2023)

Table 55. Middle East & Africa Angiogenesis Therapeutic Agent Revenue by Country (2018-2023) & (\$ Millions)

Table 56. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Market Share by Country (2018-2023)

Table 57. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Type (2018-2023) & (K Units)

Table 58. Middle East & Africa Angiogenesis Therapeutic Agent Sales by Application (2018-2023) & (K Units)

Table 59. Key Market Drivers & Growth Opportunities of Angiogenesis Therapeutic Agent

Table 60. Key Market Challenges & Risks of Angiogenesis Therapeutic Agent

Table 61. Key Industry Trends of Angiogenesis Therapeutic Agent

Table 62. Angiogenesis Therapeutic Agent Raw Material

Table 63. Key Suppliers of Raw Materials



- Table 64. Angiogenesis Therapeutic Agent Distributors List
- Table 65. Angiogenesis Therapeutic Agent Customer List
- Table 66. Global Angiogenesis Therapeutic Agent Sales Forecast by Region (2024-2029) & (K Units)
- Table 67. Global Angiogenesis Therapeutic Agent Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 68. Americas Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
- Table 69. Americas Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 70. APAC Angiogenesis Therapeutic Agent Sales Forecast by Region (2024-2029) & (K Units)
- Table 71. APAC Angiogenesis Therapeutic Agent Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 72. Europe Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
- Table 73. Europe Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 74. Middle East & Africa Angiogenesis Therapeutic Agent Sales Forecast by Country (2024-2029) & (K Units)
- Table 75. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 76. Global Angiogenesis Therapeutic Agent Sales Forecast by Type (2024-2029) & (K Units)
- Table 77. Global Angiogenesis Therapeutic Agent Revenue Forecast by Type (2024-2029) & (\$ Millions)
- Table 78. Global Angiogenesis Therapeutic Agent Sales Forecast by Application (2024-2029) & (K Units)
- Table 79. Global Angiogenesis Therapeutic Agent Revenue Forecast by Application (2024-2029) & (\$ Millions)
- Table 80. Gilead Sciences, Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors
- Table 81. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications
- Table 82. Gilead Sciences, Inc. Angiogenesis Therapeutic Agent Sales (K Units),
- Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 83. Gilead Sciences, Inc. Main Business
- Table 84. Gilead Sciences, Inc. Latest Developments
- Table 85. Eyetech Inc. Basic Information, Angiogenesis Therapeutic Agent



Manufacturing Base, Sales Area and Its Competitors

Table 86. Eyetech Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 87. Eyetech Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 88. Eyetech Inc. Main Business

Table 89. Eyetech Inc. Latest Developments

Table 90. Becton, Dickinson and Company Basic Information, Angiogenesis

Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 91. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 92. Becton, Dickinson and Company Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 93. Becton, Dickinson and Company Main Business

Table 94. Becton, Dickinson and Company Latest Developments

Table 95. Regeneron Pharmaceuticals, Inc. Basic Information, Angiogenesis

Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 96. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 97. Regeneron Pharmaceuticals, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 98. Regeneron Pharmaceuticals, Inc. Main Business

Table 99. Regeneron Pharmaceuticals, Inc. Latest Developments

Table 100. Genentech, Inc. Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 101. Genentech, Inc. Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 102. Genentech, Inc. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 103. Genentech, Inc. Main Business

Table 104. Genentech, Inc. Latest Developments

Table 105. Novartis AG Basic Information, Angiogenesis Therapeutic Agent

Manufacturing Base, Sales Area and Its Competitors

Table 106. Novartis AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 107. Novartis AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 108. Novartis AG Main Business

Table 109. Novartis AG Latest Developments



Table 110. Allergan plc Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 111. Allergan plc Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 112. Allergan plc Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 113. Allergan plc Main Business

Table 114. Allergan plc Latest Developments

Table 115. Bayer AG Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 116. Bayer AG Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 117. Bayer AG Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 118. Bayer AG Main Business

Table 119. Bayer AG Latest Developments

Table 120. Santen Pharmaceutical Co., Ltd. Basic Information, Angiogenesis

Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 121. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 122. Santen Pharmaceutical Co., Ltd. Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 123. Santen Pharmaceutical Co., Ltd. Main Business

Table 124. Santen Pharmaceutical Co., Ltd. Latest Developments

Table 125. Shanghai Pharmaceuticals Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 126. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 127. Shanghai Pharmaceuticals Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 128. Shanghai Pharmaceuticals Main Business

Table 129. Shanghai Pharmaceuticals Latest Developments

Table 130. Johnson & Johnson Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 131. Johnson & Johnson Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 132. Johnson & Johnson Angiogenesis Therapeutic Agent Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 133. Johnson & Johnson Main Business



Table 134. Johnson & Johnson Latest Developments

Table 135. Pfizer Basic Information, Angiogenesis Therapeutic Agent Manufacturing

Base, Sales Area and Its Competitors

Table 136. Pfizer Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 137. Pfizer Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million),

Price (US\$/Unit) and Gross Margin (2018-2023)

Table 138. Pfizer Main Business

Table 139. Pfizer Latest Developments

Table 140. Sun Pharma Basic Information, Angiogenesis Therapeutic Agent

Manufacturing Base, Sales Area and Its Competitors

Table 141. Sun Pharma Angiogenesis Therapeutic Agent Product Portfolios and

Specifications

Table 142. Sun Pharma Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 143. Sun Pharma Main Business

Table 144. Sun Pharma Latest Developments

Table 145. Otsuka Pharmaceutical Co. Ltd Basic Information, Angiogenesis Therapeutic

Agent Manufacturing Base, Sales Area and Its Competitors

Table 146. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Product

Portfolios and Specifications

Table 147. Otsuka Pharmaceutical Co. Ltd Angiogenesis Therapeutic Agent Sales (K

Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 148. Otsuka Pharmaceutical Co. Ltd Main Business

Table 149. Otsuka Pharmaceutical Co. Ltd Latest Developments

Table 150. Daiichi Sankyo Basic Information, Angiogenesis Therapeutic Agent

Manufacturing Base, Sales Area and Its Competitors

Table 151. Daiichi Sankyo Angiogenesis Therapeutic Agent Product Portfolios and

Specifications

Table 152. Daiichi Sankyo Angiogenesis Therapeutic Agent Sales (K Units), Revenue

(\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 153. Daiichi Sankyo Main Business

Table 154. Daiichi Sankyo Latest Developments

Table 155. ERC Labs Basic Information, Angiogenesis Therapeutic Agent

Manufacturing Base, Sales Area and Its Competitors

Table 156. ERC Labs Angiogenesis Therapeutic Agent Product Portfolios and

Specifications

Table 157. ERC Labs Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$

Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 158. ERC Labs Main Business



Table 159. ERC Labs Latest Developments

Table 160. Medicom Health care Basic Information, Angiogenesis Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 161. Medicom Health care Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 162. Medicom Health care Angiogenesis Therapeutic Agent Sales (K Units),

Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 163. Medicom Health care Main Business

Table 164. Medicom Health care Latest Developments

Table 165. Implandata ophthalmic products GmbH Basic Information, Angiogenesis

Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 166. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 167. Implandata ophthalmic products GmbH Angiogenesis Therapeutic Agent

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 168. Implandata ophthalmic products GmbH Main Business

Table 169. Implandata ophthalmic products GmbH Latest Developments

Table 170. The Geuder Group, MORCHER GmbH Basic Information, Angiogenesis

Therapeutic Agent Manufacturing Base, Sales Area and Its Competitors

Table 171. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 172. The Geuder Group, MORCHER GmbH Angiogenesis Therapeutic Agent

Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 173. The Geuder Group, MORCHER GmbH Main Business

Table 174. The Geuder Group, MORCHER GmbH Latest Developments

Table 175. Novamedika Basic Information, Angiogenesis Therapeutic Agent

Manufacturing Base, Sales Area and Its Competitors

Table 176. Novamedika Angiogenesis Therapeutic Agent Product Portfolios and Specifications

Table 177. Novamedika Angiogenesis Therapeutic Agent Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 178. Novamedika Main Business

Table 179. Novamedika Latest Developments



List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Angiogenesis Therapeutic Agent
- Figure 2. Angiogenesis Therapeutic Agent Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Angiogenesis Therapeutic Agent Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Angiogenesis Therapeutic Agent Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Angiogenesis Therapeutic Agent Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Myopic Choroidal Neovascularization
- Figure 10. Product Picture of Macular Edema
- Figure 11. Product Picture of Diabetic Retinopathy
- Figure 12. Product Picture of Macular Degeneration
- Figure 13. Global Angiogenesis Therapeutic Agent Sales Market Share by Type in 2022
- Figure 14. Global Angiogenesis Therapeutic Agent Revenue Market Share by Type (2018-2023)
- Figure 15. Angiogenesis Therapeutic Agent Consumed in Retail Pharmacies
- Figure 16. Global Angiogenesis Therapeutic Agent Market: Retail Pharmacies (2018-2023) & (K Units)
- Figure 17. Angiogenesis Therapeutic Agent Consumed in Online Pharmacies
- Figure 18. Global Angiogenesis Therapeutic Agent Market: Online Pharmacies (2018-2023) & (K Units)
- Figure 19. Angiogenesis Therapeutic Agent Consumed in Hospital Pharmacies
- Figure 20. Global Angiogenesis Therapeutic Agent Market: Hospital Pharmacies (2018-2023) & (K Units)
- Figure 21. Global Angiogenesis Therapeutic Agent Sales Market Share by Application (2022)
- Figure 22. Global Angiogenesis Therapeutic Agent Revenue Market Share by Application in 2022
- Figure 23. Angiogenesis Therapeutic Agent Sales Market by Company in 2022 (K Units)
- Figure 24. Global Angiogenesis Therapeutic Agent Sales Market Share by Company in 2022
- Figure 25. Angiogenesis Therapeutic Agent Revenue Market by Company in 2022 (\$



Million)

Figure 26. Global Angiogenesis Therapeutic Agent Revenue Market Share by Company in 2022

Figure 27. Global Angiogenesis Therapeutic Agent Sales Market Share by Geographic Region (2018-2023)

Figure 28. Global Angiogenesis Therapeutic Agent Revenue Market Share by Geographic Region in 2022

Figure 29. Americas Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)

Figure 30. Americas Angiogenesis Therapeutic Agent Revenue 2018-2023 (\$ Millions)

Figure 31. APAC Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)

Figure 32. APAC Angiogenesis Therapeutic Agent Revenue 2018-2023 (\$ Millions)

Figure 33. Europe Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)

Figure 34. Europe Angiogenesis Therapeutic Agent Revenue 2018-2023 (\$ Millions)

Figure 35. Middle East & Africa Angiogenesis Therapeutic Agent Sales 2018-2023 (K Units)

Figure 36. Middle East & Africa Angiogenesis Therapeutic Agent Revenue 2018-2023 (\$ Millions)

Figure 37. Americas Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022

Figure 38. Americas Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022

Figure 39. Americas Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)

Figure 40. Americas Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)

Figure 41. United States Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Canada Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Mexico Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)

Figure 44. Brazil Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)

Figure 45. APAC Angiogenesis Therapeutic Agent Sales Market Share by Region in 2022

Figure 46. APAC Angiogenesis Therapeutic Agent Revenue Market Share by Regions in 2022

Figure 47. APAC Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)



- Figure 48. APAC Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
- Figure 49. China Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 50. Japan Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 51. South Korea Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 52. Southeast Asia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 53. India Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 54. Australia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 55. China Taiwan Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 56. Europe Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022
- Figure 57. Europe Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022
- Figure 58. Europe Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)
- Figure 59. Europe Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
- Figure 60. Germany Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 61. France Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 62. UK Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 63. Italy Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 64. Russia Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 65. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Country in 2022
- Figure 66. Middle East & Africa Angiogenesis Therapeutic Agent Revenue Market Share by Country in 2022
- Figure 67. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Type (2018-2023)



- Figure 68. Middle East & Africa Angiogenesis Therapeutic Agent Sales Market Share by Application (2018-2023)
- Figure 69. Egypt Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 70. South Africa Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 71. Israel Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 72. Turkey Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 73. GCC Country Angiogenesis Therapeutic Agent Revenue Growth 2018-2023 (\$ Millions)
- Figure 74. Manufacturing Cost Structure Analysis of Angiogenesis Therapeutic Agent in 2022
- Figure 75. Manufacturing Process Analysis of Angiogenesis Therapeutic Agent
- Figure 76. Industry Chain Structure of Angiogenesis Therapeutic Agent
- Figure 77. Channels of Distribution
- Figure 78. Global Angiogenesis Therapeutic Agent Sales Market Forecast by Region (2024-2029)
- Figure 79. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Region (2024-2029)
- Figure 80. Global Angiogenesis Therapeutic Agent Sales Market Share Forecast by Type (2024-2029)
- Figure 81. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Type (2024-2029)
- Figure 82. Global Angiogenesis Therapeutic Agent Sales Market Share Forecast by Application (2024-2029)
- Figure 83. Global Angiogenesis Therapeutic Agent Revenue Market Share Forecast by Application (2024-2029)



I would like to order

Product name: Global Angiogenesis Therapeutic Agent Market Growth 2023-2029

Product link: https://marketpublishers.com/r/G44B82335DEFEN.html

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G44B82335DEFEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Emaii:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms